MINNEAPOLIS, MN, U.S., Aug. 30, 2021 (GLOBE NEWSWIRE) – PetVivo Holdings, Inc. (NASDAQ: PETV) (the “Company”), an emerging biomedical device company focused on commercializing innovative medical therapeutics for pets Focused, announced today it will be exhibiting at the Western Veterinary Conference September 6-9, 2021 at the Mandalay Bay Convention Center in Las Vegas, Nevada.
PetVivo intends to launch its lead product SPRYNG ™ with OsteoCushion ™ technology, a medical device injection of sterilized extracellular matrix microparticles that are wet, slippery and spongy and used to treat lameness and other joint-related ailments such as osteoarthritis. WVC is the largest veterinary conference for the western part of the United States and typically hosts more than 15,000 attendees, including many of the leading industry experts.
“We look forward to networking and building relationships with industry leaders who will help advance our first veterinary device for the treatment of osteoarthritis, SPRYNG,” said John Lai, chief executive officer of PetVivo Holdings, Inc.
For more information about PetVivo Holdings, Inc. please contact email@example.com or visit https://petvivo.com/
Conference exhibition details:
Western Veterinary Conference (WVC)
Stand number: 949
Tuesday, September 7, 2021 9:00 a.m. – 6:00 p.m.
Wednesday, September 8, 2021 9:00 a.m. – 6:00 p.m.
Thursday, September 9, 2021 9:00 a.m. – 2:00 p.m.
Location: Mandalay Bay Convention Center in Las Vegas, Nevada.
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (NASDAQ: PETV) is an emerging biomedical device company currently focused on manufacturing, marketing, and licensing innovative pet medical devices and therapeutics. The company’s strategy is to use human therapies to treat pets in a capital and time efficient manner. A key part of this strategy is accelerating sales growth in veterinary products, which hit the market much earlier than more strictly regulated pharmaceuticals and biologics.
PetVivo has a pipeline of seventeen products for the treatment of animals and humans. A portfolio of twenty-one patents protect the company’s biomaterials, products, production processes and application methods. The company’s flagship product, SPRYNG, a veterinarian-administered intra-articular injection for the treatment of osteoarthritis in dogs and horses, is expected to go on sale in the fourth quarter of this year.
John Lai, CEO
PetVivo Holdings, Inc.
Forward-looking commercial statements:
The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include all statements that are not purely historical or current fact, including, but not limited to, the Company’s proposed development and commercial timing, and which are made possible through the use of words such as “may”, “will”, ” expect “can be identified”, “project”, “estimate”, “anticipate”, “plan”, “believe”, “potentially”, “should”, “continue” or the negative versions of these words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements, including the possible listing of the company’s common stock on the Nasdaq, are based on information currently available to the company and its current plans or expectations and are subject to a number of uncertainties and risks that could materially affect current plans. Risks relating to the company’s business are fully described in the company’s Annual Report on Form 10-K for the year ended March 31, 2021 and in other periodic and current reports filed with the Securities and Exchange Commission. The company is under no obligation and expressly disclaims this obligation to update or change its forward-looking statements, whether as a result of new information, future events or for any other reason.